A new round of layoffs is hitting American workers, with major companies across the retail, technology and pharmaceutical ...
Pfizer Inc PFE shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after ...
An expert panel of the EU drug regulator endorsed six new medicines and five label expansions for approval during its October 2026 meeting held this week, marking regulatory wins for companies ...
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters ...
Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate.
Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.
Pfizer's rebound is well underway.
Pfizer is laying off 150 employees at its Portage facility, the company confirmed to FOX 17. The company says the changes are ...
Pfizer yields 6.3% and GSK yields 4.1%, and both drugmakers face major patent losses before 2030. Pfizer's dividend used a risky 89% of its free cash flow over the twelve months to June 2026, against ...
GlobalData on MSN
Pfizer partners with Enodia Therapeutics in $500m drug deal
Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at ...
(NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research ...
The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results